Omico Will Precisely Match Patients to George Clinical Oncology Trials SYDNEY, July 28, 2023 – George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program […]
Read MoreMedidata, a Dassault Systèmes company, recently announced George Clinical is implementing Medidata’s cloud-based clinical solutions – Rave Grants Manager – to improve tracking and management of budgets. Medidata’s solution will also empower George Clinical to bring operational efficiency and improve patient recruitment by sites. The implementation will give George Clinical’s global clients the usage of […]
Read MoreSYDNEY, June 27, 2023 – George Clinical and EPS Corporation (EPS), a global CRO based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian populations. In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region. […]
Read MoreGeorge Clinical recently received the award for Clinical Research Team of the Year at the 7th Annual Citeline Awards held in Boston, MA. As a 2023 winner, the George Clinical team won recognition for a multi-site program in the Asia Pacific region that recruited more than 3,000 patients across 14 sites in just seven weeks. […]
Read MoreFrost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in kidney research, oncology and neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has […]
Read MoreSYDNEY, May 4, 2023 – George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing […]
Read MoreAs part of our Corporate Social Responsibility (CSR) initiative, George Clinical India in collaboration with Trinity Care Foundation (an NGO) intends to distribute Hearing Aids for Hearing Impaired Children & Assistive Aids for Children with Disabilities from the marginalized sections of the community. Hearing loss can affect a child’s ability to develop communication, language, and […]
Read MoreFierce Pharma recently reported that GSK’s oral anemia drug, Jesduvroq, has scored partial FDA approval after two rivals previously suffered rejections. George Clinical’s global and national scientific leadership helped move the breakthrough CKD anemia treatment forward via the collaboration between the organization’s exceptional kidney and metabolic scientific leadership network and GSK. The network provided continuity, […]
Read MoreSYDNEY, December 9, 2022 – George Clinical announces that it has entered into a sale agreement with Hillhouse, a global investment firm with deep experience in partnering with and supporting healthcare businesses. The transaction will allow George Clinical to continue a path of rapid global expansion, leadership in Asia-Pacific clinical research services, and will provide considerable […]
Read MoreOVERLAND PARK, Ks., October 25, 2022 – George Clinical, in close collaboration with The George Institute for Global Health, has recently announced the recruitment of more than 5,000 patients in its ground-breaking, first of its kind, Global Kidney Patient Trials Network (GKPTN) which will accelerate treatments for kidney disease. The concept for the GKPTN is […]
Read More
